Company Biovica International AB

Equities

BIOVIC B

SE0008613731

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per region

Ratings for Biovica International AB

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Diagnostics & Testing

Delayed Nasdaq Stockholm Other stock markets 09:17:14 30/04/2024 BST			5-day change	1st Jan Change
1.65 ^SEK	+3.25%		-13.16%	-36.05%

04-13	Certain B Shares of Biovica International AB are subject to a Lock-Up Agreement Ending on 13-APR-2024.	CI
04-12	Biovica International AB Announces Divitum® Tka in Observational Trial	CI

Biovica International AB is a Sweden-based biotechnology company. It develops and commercializes blood-based biomarker assays for the monitoring of cancer therapies and for prediction of patient outcome. The Company has focus on breast cancer and its main product DiviTum is a blood-based test, which measures the activity of the enzyme thymidine kinase-1 (TK) in blood serum or cell cultures. The Company collaborates with numerous institutions, such as Karolinska Institutet in Sweden and Dana Farber Cancer Institute, Washington University, Baylor College of Medicine, City of Hope Research & Treatment Center in the Unites States, as well as The International Breast Cancer Study Group (IBCSG) based in Switzerland and Breast International Group in Belgium.

Number of employees: 37

SEK in Million	2022	Weight	2023	Weight	Delta
Blood-based Biomarker Assays 100.0 %	2	100.0 %	3	100.0 %	+65.43%

SEK in Million	2022	Weight	2023	Weight	Delta
United States 96.3 %	2	95.0 %	3	96.3 %	+67.68%
European Union excluding Sweden 3.7 %	0	5.0 %	0	3.7 %	+22.55%

Managers	Title	Age	Since
Anders Rylander CEO	Chief Executive Officer	54	31/12/09
Anders Morén DFI	Director of Finance/CFO	59	31/12/22
Hanna Ritzen CTO	Chief Tech/Sci/R&D Officer	45	31/12/21
Tomas Andersson COO	Chief Operating Officer	64	31/12/19
Joakim Arwidson LAW	General Counsel	56	31/12/20
Helle Fisker SAM	Sales & Marketing	55	31/12/20
Henrik Bernhard Winther PRN	Corporate Officer/Principal	58	17/11/19

Members of the board	Title	Age	Since
Lars Erik Holmqvist CHM	Chairman	64	19/03/19
Annika Berg BRD	Director/Board Member	61	31/12/19
Maria Holmlund BRD	Director/Board Member	68	31/12/15
Jarl Ulf Birger Jungnelius BRD	Director/Board Member	73	31/12/13
Anders Rylander CEO	Chief Executive Officer	54	31/12/09
Jesper Söderqvist BRD	Director/Board Member	58	31/12/12
Henrik Osvald BRD	Director/Board Member	65	31/12/18
Marie-Louise Fjaellskog BRD	Director/Board Member	59	31/12/19

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	0	6,271,293	0	0	92.54 %
Stock B	1	77,784,267	77,784,267 ( 100.00 %)	0

Name	Equities	%	Valuation
Henrik Osvald 0.8534 %	663,847	0.8534 %	152 731 kr
Gunnar Rylander 0.7488 %	582,442	0.7488 %	134 002 kr
Lars Erik Holmqvist 0.7426 %	577,615	0.7426 %	132 892 kr
Andra AP-fonden 0.6495 %	505,247	0.6495 %	116 242 kr
LYM Consulting AB 0.6072 %	472,343	0.6072 %	108 672 kr
Mattias Sesemann 0.5492 %	427,189	0.5492 %	98 283 kr
Anders Rylander 0.5193 %	403,938	0.5193 %	92 934 kr
Ålandsbanken Abp (Invt Mgmt) 0.3791 %	294,903	0.3791 %	67 848 kr
Tellus Fonder AB 0.0276 %	21,500	0.0276 %	4 947 kr

Name	Equities	%	Valuation
Anders Rylander 53.99 %	3,575,640	53.99 %	822 647 kr
Gunnar Rylander 14.43 %	955,723	14.43 %	219 883 kr
Kristina Gronowitz 6.215 %	411,660	6.215 %	94 711 kr

Biovica International AB

Dag Hammarskjölds väg 54B Uppsala Science Park

752 37, Uppsala

+46 1 84 44 48 30

http://www.biovica.com

address Biovica International AB(BIOVIC B)

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

1.598 SEK

Average target price

15 SEK

Spread / Average Target

+838.67%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Diagnostics & Testing

	1st Jan change	Capi.
BIOVICA INTERNATIONAL AB	-36.05%	12.29M
EXACT SCIENCES CORPORATION	-20.55%	10.81B
IOVANCE BIOTHERAPEUTICS, INC.	+47.97%	3.36B
GUARDANT HEALTH, INC.	-32.75%	2.22B
BGI GENOMICS CO., LTD.	-14.15%	2.16B
VERACYTE, INC.	-26.06%	1.55B
MARAVAI LIFESCIENCES HOLDINGS, INC.	+19.85%	1.04B
SEEGENE, INC.	-2.62%	746M
CAREDX, INC	-31.67%	425M
ADAPTIVE BIOTECHNOLOGIES CORPORATION	-43.88%	405M

Bio Diagnostics & Testing